BRCA1, BRCA2 and PALB2 mRNA Expression as Prognostic Markers in Patients with Early Breast Cancer

被引:1
|
作者
Shehaj, Ina [1 ]
Krajnak, Slavomir [1 ]
Almstedt, Katrin [1 ]
Degirmenci, Yaman [1 ]
Herzog, Sophia [1 ]
Lebrecht, Antje [1 ]
Linz, Valerie Catherine [1 ]
Schwab, Roxana [1 ]
Stewen, Kathrin [1 ]
Brenner, Walburgis [1 ]
Hasenburg, Annette [1 ]
Schmidt, Marcus [1 ]
Heimes, Anne-Sophie [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Obstet & Gynecol, D-55131 Mainz, Germany
关键词
mRNA expression; BRCA1; BRCA2; PALB2; metagene; breast cancer; HETEROGENEITY; PROTEIN; IMPACT;
D O I
10.3390/biomedicines12061361
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer (BC) poses a challenge in establishing new treatment strategies and identifying new prognostic and predictive markers due to the extensive genetic heterogeneity of BC. Very few studies have investigated the impact of mRNA expression of these genes on the survival of BC patients. Methods: We examined the impact of the mRNA expression of breast cancer gene type 1 (BRCA1), breast cancer gene type 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) on the metastasis-free survival (MFS) of patients with early BC using microarray gene expression analysis. Results: The study was performed in a cohort of 461 patients with a median age of 62 years at initial diagnosis. The median follow-up time was 147 months. We could show that the lower expression of BRCA1 and BRCA2 is significantly associated with longer MFS (p < 0.050). On the contrary, the lower expression of PALB2 was correlated with a shorter MFS (p = 0.049). Subgroup survival analysis identified the prognostic influence of mRNA expression for BRCA1 among patients with luminal-B-like BC and for BRCA2 and PALB2 in the subset of patients with luminal-A-like BC (p < 0.050). Conclusions: According to our observations, BRCA1, BRCA2, and PALB2 expression might become valuable biomarkers of disease progression.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] BRCA2 AND BRCA1 breast cancer phenotypes
    Marcus, JN
    Watson, P
    Page, DL
    Narod, SA
    Tonin, P
    Serova, O
    Lenoir, GM
    Lynch, HT
    LABORATORY INVESTIGATION, 1997, 76 (01) : 110 - 110
  • [42] Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina
    Roxana Cerretini
    Graciela Mercado
    Josh Morganstein
    Jorge Schiaffi
    Mónica Reynoso
    Diana Montoya
    Rita Valdéz
    Steven A. Narod
    Mohammad R. Akbari
    Breast Cancer Research and Treatment, 2019, 178 : 629 - 636
  • [43] PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations
    Jin Ho Kim
    Doo Ho Choi
    Dae Yeon Cho
    Sei Hyun Ahn
    Byung Ho Son
    Bruce G. Haffty
    Breast Cancer Research and Treatment, 2010, 122 : 303 - 306
  • [44] BRCA1 and BRCA2 mutations in patients with familial breast cancer
    Bolufer, P
    Munárriz, B
    Santaballa, A
    Velasco, E
    Lerma, E
    Barragán, E
    MEDICINA CLINICA, 2005, 124 (01): : 10 - 12
  • [45] PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations
    Kim, Jin Ho
    Choi, Doo Ho
    Cho, Dae Yeon
    Ahn, Sei Hyun
    Son, Byung Ho
    Haffty, Bruce G.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (01) : 303 - 306
  • [46] BRCA1 AND BRCA2 IN MALAYSIAN BREAST CANCER PATIENTS.
    Teo, S. H.
    Thirthagiri, E.
    Lee, S. Y.
    Kang, P.
    Lee, D. S.
    Yoon, S.
    Taib, N. A. Mohd
    Thong, M. K.
    Yip, C. H.
    ANNALS OF ONCOLOGY, 2009, 20 : 40 - 40
  • [47] Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
    Yadav, Siddhartha
    Boddicker, Nicholas J.
    Na, Jie
    Polley, Eric C.
    Hu, Chunling
    Hart, Steven N.
    Gnanaolivu, Rohan D.
    Larson, Nicole
    Holtegaard, Susan
    Huang, Huaizhi
    Dunn, Carolyn A.
    Teras, Lauren R.
    Patel, Alpa V.
    Lacey, James V.
    Neuhausen, Susan L.
    Martinez, Elena
    Haiman, Christopher
    Chen, Fei
    Ruddy, Kathryn J.
    Olson, Janet E.
    John, Esther M.
    Kurian, Allison W.
    Sandler, Dale P.
    O'Brien, Katie M.
    Taylor, Jack A.
    Weinberg, Clarice R.
    Anton-Culver, Hoda
    Ziogas, Argyrios
    Zirpoli, Gary
    Goldgar, David E.
    Palmer, Julie R.
    Domchek, Susan M.
    Weitzel, Jeffrey N.
    Nathanson, Katherine L.
    Kraft, Peter
    Couch, Fergus J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1703 - +
  • [48] Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
    Shoko Takeuchi
    Manami Doi
    Naoki Ikari
    Masakazu Yamamoto
    Toru Furukawa
    Scientific Reports, 8
  • [49] Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
    Takeuchi, Shoko
    Doi, Manami
    Ikari, Naoki
    Yamamoto, Masakazu
    Furukawa, Toru
    SCIENTIFIC REPORTS, 2018, 8
  • [50] Characterising cancer risks for carriers of mutations in BRCA1, BRCA2, PALB2, and RAD51C genes
    Antoniou, Antonis C.
    CANCER RESEARCH, 2015, 75